Ali McBride, PharmD, MS, BCOP, discusses the oncology community’s reaction to biosimilars for rituximab (Rituxan).
Ali McBride, PharmD, MS, BCOP
Advertisement
Articles by Ali McBride, PharmD, MS, BCOP
Ali McBride, PharmD, MS, BCOP, Clinical Coordinator of Hematology/Oncology, The University of Arizona Cancer Center, and President-Elect of the Association of Community Cancer Centers (ACCC), discusses the potential impact of bevacizumab (Avastin) biosimilars in oncology.
Ali McBride, PharmD, MS, BCOP, Clinical Coordinator of Hematology/Oncology, The University of Arizona Cancer Center, and President-Elect of the Association of Community Cancer Centers.
Advertisement
Latest Updated Articles
Dr. McBride Discusses Financial Toxicity in OncologyPublished: June 14th 2018 | Updated:
Dr. McBride on the Potential Impact of Bevacizumab Biosimilars in OncologyPublished: August 9th 2019 | Updated:
Dr. McBride on Biosimilar RituximabPublished: September 27th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5